|
Strategic Partnerships
ApoImmune is building both drug discovery and clinical development capabilities that can support various research and development projects. Currently, we are concentrating our clinical capabilities on cancer as we start our first Phase I clinical trial. Our other research programs include infectious diseases, Type 1 diabetes and cell/organ transplantation. To maximize the value of our proprietary technologies and products, ApoImmune seeks to collaborate or partner with research institutions and pharmaceutical and biotechnology companies.
For further information on strategic partnerships please contact one of the following:
Business Development Inquiries:
Steven Downey
President and CEO
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493
sdowney[at]apoimmune.com
Scientific Inquiries:
Dr. Rolf Huseby, Ph.D.
Vice President, Advanced Research and Product Development
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493
rhuseby[at]apoimmune.com
|
|
|
